[The value of the treatment of post-radiotherapy hyposialorrhoea by dihydroergotamine (author's transl)].
This study of the Rennes anti-cancer Center reports the results of a clinical and isotope scan study of Dihydroergotamine-Sandoz in the treatment of post-radiotherapy hyposialorrhoea. Dihydroergotamine was used at an initial dose of 100 drops 3 times per day for two weeks, then 60 drops 3 times per day. Treatment must be continued for several months. The results of such treatment given to 11 patients in comparison with a "control" group of 19 patients were evaluated objectively using isotope studies of salivary function. It was found, in addition, that the interruption of treatment might be associated with a relapse of symptoms, reversible when the drug was restarted. Finally, and in the light of the results of this study, it would appear to be logical to treat patients immediately following the end of radiotherapy without awaiting the first symptoms of hyposialorrhoea.
D004087:Dihydroergotamine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009333:Neck; D011877:Radionuclide Imaging; D011878:Radiotherapy / Q000009:adverse effects*; D012469:Salivary Glands / Q000000981:diagnostic imaging; D012472:Salivation; D014987:Xerostomia / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology
D004087:Dihydroergotamine
Intérêt du traitement des hyposialorrhées post-radiothérapiques par la dihydroergotamine.